Publicaciones en las que colabora con JUAN PASQUAU LIAÑO (29)

2024

  1. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain

    Viruses, Vol. 16, Núm. 2

2023

  1. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 3

2022

  1. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

    Viruses, Vol. 14, Núm. 3

  2. Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections

    Scientific Reports, Vol. 12, Núm. 1

  3. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV

    Viruses, Vol. 14, Núm. 12

  4. Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a stablished antimicrobial stewardship program

    Revista Espanola de Quimioterapia, Vol. 35, pp. 102-107

2021

  1. Effectiveness of the quadrivalent hpv vaccine in preventing anal ≥ hsils in a spanish population of hiv+ msm aged > 26 years

    Viruses, Vol. 13, Núm. 2

  2. Risk factors for ≥high-grade anal intraepithelial lesions in MSM living with HIV and the response to topical and surgical treatments

    PLoS ONE, Vol. 16, Núm. 2 February

2019

  1. ART is key to clearing oncogenic HPV genotypes (HR-HPV) in anal mucosa of HIV-positive MSM

    PLoS ONE, Vol. 14, Núm. 10

  2. Clinical outcomes of carbapenem de-escalation regardless of microbiological results: A propensity score analysis

    International Journal of Infectious Diseases, Vol. 85, pp. 80-87

  3. DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

    Annals of Clinical Microbiology and Antimicrobials, Vol. 18, Núm. 1

  4. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients

    Medicine (United States), Vol. 98, Núm. 32

  5. Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: A preliminary

    BMC Infectious Diseases, Vol. 19, Núm. 1

2018

  1. 5. Antibacterianos

    Manejo práctico de los antimicrobianos en medicina (Avicam), pp. 27-110

  2. High prevalence and incidence of HPV-related anal cancer precursor lesions in HIV-positive women in the late HAART era

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 9, pp. 555-562

  3. High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial

    PLoS ONE, Vol. 13, Núm. 4

2017

  1. 5. Antibacterianos

    Manejo práctico de los antimicrobianos en medicina (Avicam), pp. 27-102

  2. Risk factors for infection by oncogenic human papillomaviruses in HIV-positive MSM patients in the ART era (2010-2016)

    Medicine (United States), Vol. 96, Núm. 39

  3. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)

    AIDS Research and Therapy, Vol. 14, Núm. 1

2016

  1. Effect of monotherapy with darunavir/ ritonavir on viral load in seminal fluid, and quality parameters of semen in HIV-1-Positive patients

    PLoS ONE, Vol. 11, Núm. 7